# Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142

Study · id `cardio:ct-nct02552238` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02552238](<https://clinicaltrials.gov/study/NCT02552238>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02552238

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 174 participants.

## Technical summary

Registry record NCT02552238. Allocation not applicable; no masking; primary purpose diagnostic. Start 2015-10-12 (actual); primary completion 2017-06-22 (actual). Results posted on 2020-08-05.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 3
- Enrolled: 174 participants (enrolled count; ClinicalTrials.gov record NCT02552238, source copy `cardio:ctgov-nct02552238-2021-07-07`, retrieved 2026-10-26)
- Started: 2015-10-12 (actual) (ClinicalTrials.gov record NCT02552238, source copy `cardio:ctgov-nct02552238-2021-07-07`, retrieved 2026-10-26)
- Primary completion: 2017-06-22 (actual) (ClinicalTrials.gov record NCT02552238, source copy `cardio:ctgov-nct02552238-2021-07-07`, retrieved 2026-10-26)
- Completion: 2018-02-25 (actual) (ClinicalTrials.gov record NCT02552238, source copy `cardio:ctgov-nct02552238-2021-07-07`, retrieved 2026-10-26)
- Results first posted: 2020-08-05 (ClinicalTrials.gov record NCT02552238, source copy `cardio:ctgov-nct02552238-2021-07-07`, retrieved 2026-10-26)
- Countries: United States; Belgium; Canada; United Kingdom (ClinicalTrials.gov record NCT02552238, source copy `cardio:ctgov-nct02552238-2021-07-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02552238-2021-07-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142
- Condition: Coronary Artery Disease
- Intervention (Drug): Lumason
- Lead sponsor: Bracco Diagnostics, Inc
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Bracco Diagnostics, Inc (`cardio:org-bracco-diagnostics-inc`)

## Provenance

Content hash: 1105c98fd2c7c85b07da905be69e7a7f04df93a28674313d4e3a4adbd7229d49
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
